Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-cash Items (2016 - 2025)

Heron Therapeutics' Non-cash Items history spans 11 years, with the latest figure at $11.8 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 23.13% year-over-year to $11.8 million; the TTM value through Dec 2025 reached $11.8 million, up 23.13%, while the annual FY2025 figure was $11.8 million, 23.13% up from the prior year.
  • Non-cash Items reached $11.8 million in Q4 2025 per HRTX's latest filing, up from $9.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $12.2 million in Q4 2021 to a low of $2.8 million in Q4 2023.
  • Average Non-cash Items over 4 years is $9.1 million, with a median of $10.7 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: crashed 82.28% in 2021, then surged 242.46% in 2024.
  • A 4-year view of Non-cash Items shows it stood at $12.2 million in 2021, then tumbled by 77.13% to $2.8 million in 2023, then soared by 242.46% to $9.6 million in 2024, then rose by 23.13% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Non-cash Items are $11.8 million (Q4 2025), $9.6 million (Q4 2024), and $2.8 million (Q4 2023).